全文获取类型
收费全文 | 488篇 |
免费 | 179篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 10篇 |
儿科学 | 11篇 |
妇产科学 | 6篇 |
基础医学 | 1篇 |
口腔科学 | 66篇 |
临床医学 | 139篇 |
内科学 | 151篇 |
皮肤病学 | 9篇 |
神经病学 | 63篇 |
特种医学 | 25篇 |
外科学 | 103篇 |
预防医学 | 31篇 |
眼科学 | 2篇 |
药学 | 4篇 |
肿瘤学 | 52篇 |
出版年
2024年 | 4篇 |
2023年 | 33篇 |
2022年 | 14篇 |
2021年 | 24篇 |
2020年 | 31篇 |
2019年 | 28篇 |
2018年 | 49篇 |
2017年 | 48篇 |
2016年 | 44篇 |
2015年 | 47篇 |
2014年 | 37篇 |
2013年 | 39篇 |
2012年 | 12篇 |
2011年 | 17篇 |
2010年 | 38篇 |
2009年 | 36篇 |
2008年 | 22篇 |
2007年 | 10篇 |
2006年 | 15篇 |
2005年 | 7篇 |
2004年 | 1篇 |
2003年 | 2篇 |
2002年 | 7篇 |
2001年 | 9篇 |
2000年 | 4篇 |
1999年 | 7篇 |
1998年 | 12篇 |
1997年 | 10篇 |
1996年 | 14篇 |
1995年 | 10篇 |
1994年 | 10篇 |
1993年 | 8篇 |
1992年 | 5篇 |
1991年 | 2篇 |
1990年 | 5篇 |
1989年 | 1篇 |
1988年 | 4篇 |
1987年 | 1篇 |
1985年 | 1篇 |
1982年 | 2篇 |
1981年 | 2篇 |
1980年 | 1篇 |
排序方式: 共有673条查询结果,搜索用时 0 毫秒
671.
Steven Boonen MD PhD Dennis M. Black PhD Cathleen S. Colón‐Emeric MD MHSc Richard Eastell MD Jay S. Magaziner PhD Erik Fink Eriksen MD DMSc Peter Mesenbrink PhD Patrick Haentjens MD PhD Kenneth W. Lyles MD 《Journal of the American Geriatrics Society》2010,58(2):292-299
OBJECTIVES: To determine the efficacy of once‐yearly intravenous zoledronic acid (ZOL) 5 mg in reducing risk of clinical vertebral, nonvertebral, and any clinical fractures in elderly osteoporotic postmenopausal women. DESIGN: A post hoc subgroup analysis of pooled data from the Health Outcome and Reduced Incidence with Zoledronic Acid One Yearly (HORIZON) Pivotal Fracture Trial and the HORIZON Recurrent Fracture Trial. SETTING: Multicenter, randomized, double‐blind, placebo‐controlled trials. PARTICIPANTS: Postmenopausal women (aged ≥75) with documented osteoporosis (T‐score ≤?2.5 at femoral neck or ≥1 prevalent vertebral or hip fracture) or a recent hip fracture. INTERVENTION: Patients were randomized to receive an intravenous infusion of ZOL 5 mg (n=1,961) or placebo (n=1,926) at baseline and 12 and 24 months. MEASUREMENTS: Primary endpoints were incidence of clinical vertebral and nonvertebral and any clinical fracture after treatment. RESULTS: At 3 years, incidence of any clinical, clinical vertebral, and nonvertebral fracture were significantly lower in the ZOL group than in the placebo group (10.8% vs 16.6%, 1.1% vs 3.7%, and 9.9% vs 13.7%, respectively) (hazard ratio (HR)=0.65, 95% confidence interval (CI)=0.54–0.78, P<.001; HR=0.34, 95% CI=0.21–0.55, P<.001; and HR=0.73, 95% CI=0.60–0.90, P=.002, respectively). The incidence of hip fracture was lower with ZOL but did not reach statistical significance. The incidence rate of postdose adverse events were higher with ZOL, although the rate of serious adverse events and deaths was comparable between the two groups. CONCLUSION: Once‐yearly intravenous ZOL 5 mg was associated with a significant reduction in the risk of new clinical fractures (vertebral and nonvertebral) in elderly postmenopausal women with osteroporosis. 相似文献
672.
Assessment of interleukin‐1β, interleukin‐6, and tumor necrosis factor‐Α levels in the peri‐implant sulcular fluid among waterpipe (narghile) smokers and never‐smokers with peri‐implantitis 下载免费PDF全文
673.
A New Method for Sham‐Controlled Acupuncture in Experimental Visceral Pain – a Randomized,Single‐Blinded Study 下载免费PDF全文